Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Neurogene Inc. (NGNE) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Neurogene Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1404644.
Total stock buying since 2014: $132,546,492.
Total stock sales since 2014: $44,650,510.
Total stock option exercises since 2014: $579,200.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 11,298 | $179,247 | 0 | $0 |
| 2024 | 120,270 | $2,742,464 | 0 | $0 | 0 | $0 |
| 2023 | 0 | $0 | 22,788 | $13,988 | 62,500 | $0 |
| 2022 | 0 | $0 | 7,193 | $8,390 | 15,000 | $0 |
| 2021 | 200,000 | $1,408,910 | 40,697 | $490,164 | 25,000 | $0 |
| 2020 | 618,300 | $8,504,040 | 19,668 | $226,427 | 0 | $0 |
| 2019 | 3,758,114 | $28,243,668 | 0 | $0 | 0 | $0 |
| 2018 | 0 | $0 | 5,208 | $68,537 | 5,208 | $54,996 |
| 2017 | 398,062 | $6,483,633 | 15,625 | $207,243 | 15,625 | $150,000 |
| 2016 | 3,788,760 | $43,620,638 | 0 | $0 | 0 | $0 |
| 2015 | 2,485,207 | $38,543,142 | 1,839,714 | $43,067,887 | 64,966 | $374,204 |
| 2014 | 272,727 | $2,999,997 | 50,000 | $388,627 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-05 | 0 | $0 | 6,797 | $103,001 | 0 | $0 |
| 2025-03 | 0 | $0 | 4,501 | $76,246 | 0 | $0 |
| 2024-11 | 120,270 | $2,742,464 | 0 | $0 | 0 | $0 |
| 2023-08 | 0 | $0 | 1,323 | $817 | 5,000 | $0 |
| 2023-04 | 0 | $0 | 3,769 | $2,608 | 0 | $0 |
| 2023-03 | 0 | $0 | 0 | $0 | 10,000 | $0 |
| 2023-02 | 0 | $0 | 17,696 | $10,563 | 47,500 | $0 |
| 2022-08 | 0 | $0 | 1,655 | $1,640 | 5,000 | $0 |
| 2022-05 | 0 | $0 | 5,538 | $6,750 | 0 | $0 |
| 2022-04 | 0 | $0 | 0 | $0 | 10,000 | $0 |
| 2021-08 | 150,000 | $933,550 | 0 | $0 | 0 | $0 |
| 2021-06 | 50,000 | $475,360 | 1,800 | $18,714 | 0 | $0 |
| 2021-05 | 0 | $0 | 3,600 | $39,246 | 0 | $0 |
| 2021-04 | 0 | $0 | 9,000 | $110,988 | 0 | $0 |
| 2021-03 | 0 | $0 | 15,497 | $178,332 | 25,000 | $0 |
| 2021-02 | 0 | $0 | 10,800 | $142,884 | 0 | $0 |
| 2020-07 | 424,000 | $6,466,000 | 0 | $0 | 0 | $0 |
| 2020-04 | 81,800 | $936,365 | 19,668 | $226,427 | 0 | $0 |
| 2020-03 | 112,500 | $1,101,675 | 0 | $0 | 0 | $0 |
| 2019-12 | 3,136,589 | $26,347,346 | 0 | $0 | 0 | $0 |
| 2019-09 | 250,000 | $781,798 | 0 | $0 | 0 | $0 |
| 2019-08 | 371,525 | $1,114,524 | 0 | $0 | 0 | $0 |
| 2018-05 | 0 | $0 | 3,906 | $49,489 | 3,906 | $41,247 |
| 2018-03 | 0 | $0 | 1,302 | $19,048 | 1,302 | $13,749 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-05-14 | Cobb Stuart (Chief Scientific Officer) | Sale | 6,797 | 15.15 | 103,001 |
| 2025-03-13 | Cvijic Christine Mikail (President and CFO) | Sale | 4,501 | 16.94 | 76,246 |
| 2024-11-26 | Akkaraju Srinivas | Buy | 48,770 | 26.29 | 1,282,065 |
| 2024-11-22 | Mcminn Rachel (Chief Executive Officer) | Buy | 47,500 | 20.40 | 968,999 |
| 2024-11-22 | Cvijic Christine Mikail (President and CFO) | Buy | 24,000 | 20.48 | 491,400 |
| 2023-08-11 | Smith Sean Michael (Interim CFO, Prin Acct Officer) | Sale | 1,323 | .62 | 817 |
| 2023-08-10 | Smith Sean Michael (Interim CFO, Prin Acct Officer) | Option Ex | 5,000 | .00 | 0 |
| 2023-04-03 | Patel Priti (Other) | Sale | 3,769 | .69 | 2,608 |
| 2023-03-31 | Patel Priti (Other) | Option Ex | 10,000 | .00 | 0 |
| 2023-02-02 | Smith Sean Michael (Principal Accounting Officer) | Sale | 3,316 | .60 | 1,979 |
| 2023-02-02 | Patel Priti (Chief Medical Officer) | Sale | 14,380 | .60 | 8,584 |
| 2023-02-01 | Smith Sean Michael (Principal Accounting Officer) | Option Ex | 12,500 | .00 | 0 |
| 2023-02-01 | Patel Priti (Chief Medical Officer) | Option Ex | 35,000 | .00 | 0 |
| 2022-08-10 | Smith Sean Michael (Principal Accounting Officer) | Sale | 1,655 | .99 | 1,640 |
| 2022-08-10 | Smith Sean Michael (Principal Accounting Officer) | Option Ex | 5,000 | .00 | 0 |
| 2022-05-02 | Patel Priti (Chief Medical Officer) | Sale | 5,538 | 1.22 | 6,750 |
| 2022-04-30 | Patel Priti (Chief Medical Officer) | Option Ex | 10,000 | .00 | 0 |
| 2021-08-25 | Drachman Jonathan G (President and CEO) | Buy | 50,000 | 6.45 | 322,450 |
| 2021-08-24 | Drachman Jonathan G (President and CEO) | Buy | 100,000 | 6.11 | 611,100 |
| 2021-06-16 | Walkey Carl (Senior Vice President) | Sale | 600 | 10.19 | 6,114 |
| 2021-06-08 | Walkey Carl (Senior Vice President) | Sale | 600 | 11.00 | 6,600 |
| 2021-06-04 | Walkey Carl (Senior Vice President) | Sale | 600 | 10.00 | 6,000 |
| 2021-06-04 | Drachman Jonathan G (President and CEO) | Buy | 10,000 | 9.61 | 96,080 |
| 2021-06-03 | Drachman Jonathan G (President and CEO) | Buy | 40,000 | 9.48 | 379,280 |
| 2021-05-26 | Walkey Carl (Senior Vice President) | Sale | 600 | 10.00 | 6,000 |
| 2021-05-19 | Walkey Carl (Senior Vice President) | Sale | 600 | 10.63 | 6,378 |
| 2021-05-12 | Walkey Carl (Senior Vice President) | Sale | 1,200 | 11.09 | 13,308 |
| 2021-05-05 | Walkey Carl (Senior Vice President) | Sale | 1,200 | 11.30 | 13,560 |
| 2021-04-28 | Walkey Carl (Senior Vice President) | Sale | 2,400 | 12.58 | 30,192 |
| 2021-04-26 | Walkey Carl (Senior Vice President) | Sale | 600 | 13.00 | 7,800 |
| 2021-04-21 | Walkey Carl (Senior Vice President) | Sale | 1,800 | 11.98 | 21,564 |
| 2021-04-14 | Walkey Carl (Senior Vice President) | Sale | 1,800 | 12.22 | 21,996 |
| 2021-04-07 | Walkey Carl (Senior Vice President) | Sale | 1,800 | 12.02 | 21,636 |
| 2021-04-05 | Walkey Carl (Senior Vice President) | Sale | 600 | 13.00 | 7,800 |
| 2021-03-31 | Walkey Carl (Senior Vice President) | Sale | 1,800 | 11.96 | 21,528 |
| 2021-03-24 | Walkey Carl (Senior Vice President) | Sale | 1,800 | 11.95 | 21,515 |
| 2021-03-22 | Walkey Carl (Senior Vice President) | Sale | 600 | 12.00 | 7,200 |
| 2021-03-17 | Walkey Carl (Senior Vice President) | Sale | 1,200 | 11.36 | 13,632 |
| 2021-03-17 | Ho Robert (Chief Financial Officer) | Sale | 6,497 | 11.01 | 71,557 |
| 2021-03-16 | Ho Robert (Chief Financial Officer) | Option Ex | 25,000 | .00 | 0 |
| 2021-03-10 | Walkey Carl (Senior Vice President) | Sale | 1,800 | 11.97 | 21,540 |
| 2021-03-03 | Walkey Carl (Senior Vice President) | Sale | 1,800 | 11.87 | 21,360 |
| 2021-02-25 | Walkey Carl (Senior Vice President) | Sale | 600 | 13.00 | 7,800 |
| 2021-02-24 | Walkey Carl (Senior Vice President) | Sale | 1,800 | 12.14 | 21,852 |
| 2021-02-17 | Walkey Carl (Senior Vice President) | Sale | 2,400 | 12.70 | 30,480 |
| 2021-02-10 | Walkey Carl (Senior Vice President) | Sale | 3,000 | 14.20 | 42,600 |
| 2021-02-05 | Walkey Carl (Senior Vice President) | Sale | 600 | 14.00 | 8,400 |
| 2021-02-03 | Walkey Carl (Senior Vice President) | Sale | 2,400 | 13.23 | 31,752 |
| 2020-07-07 | Baker Julian (Director) | Buy | 424,000 | 15.25 | 6,466,000 |
| 2020-04-02 | Green Jeremy | Buy | 39,300 | 11.61 | 456,115 |
| 2020-04-02 | Green Jeremy | Sale | 9,834 | 11.56 | 113,700 |
| 2020-04-01 | Green Jeremy | Buy | 42,500 | 11.30 | 480,250 |
| 2020-04-01 | Green Jeremy | Sale | 9,834 | 11.46 | 112,727 |
| 2020-03-31 | Green Jeremy | Buy | 30,000 | 10.45 | 313,350 |
| 2020-03-30 | Green Jeremy | Buy | 32,500 | 10.09 | 327,925 |
| 2020-03-27 | Green Jeremy | Buy | 50,000 | 9.21 | 460,400 |
| 2019-12-20 | Drachman Jonathan G (President and CEO) | Buy | 119,047 | 8.40 | 999,994 |
| 2019-12-20 | Baker Bros. Advisors (gp) Llc (Director) | Buy | 3,017,542 | 8.40 | 25,347,352 |
| 2019-09-11 | Drachman Jonathan G (See Remarks) | Buy | 136,436 | 3.30 | 449,965 |
| 2019-09-10 | Drachman Jonathan G (See Remarks) | Buy | 36,742 | 3.08 | 113,275 |
| 2019-09-09 | Drachman Jonathan G (See Remarks) | Buy | 76,822 | 2.85 | 218,558 |
| 2019-08-07 | Baker Julian (Director) | Buy | 289,725 | 3.04 | 882,212 |
| 2019-08-06 | Baker Julian (Director) | Buy | 81,800 | 2.84 | 232,312 |
| 2018-05-14 | Levitt Daniel J (Director) | Sale | 3,906 | 12.67 | 49,489 |
| 2018-05-14 | Levitt Daniel J (Director) | Option Ex | 3,906 | 10.56 | 41,247 |
| 2018-03-15 | Mackenzie Lloyd (Chief Operating Officer) | Sale | 1,302 | 14.63 | 19,048 |
| 2018-03-15 | Mackenzie Lloyd (Chief Operating Officer) | Option Ex | 1,302 | 10.56 | 13,749 |
| 2017-06-05 | Main David (President and CEO) | Sale | 3,625 | 13.16 | 47,697 |
| 2017-06-05 | Main David (President and CEO) | Option Ex | 3,625 | 9.60 | 34,800 |
| 2017-06-02 | Main David (President and CEO) | Sale | 6,000 | 13.59 | 81,558 |
| 2017-06-02 | Main David (President and CEO) | Option Ex | 6,000 | 9.60 | 57,600 |
| 2017-06-01 | Main David (President and CEO) | Sale | 6,000 | 13.00 | 77,988 |
| 2017-06-01 | Main David (President and CEO) | Option Ex | 6,000 | 9.60 | 57,600 |
| 2017-01-09 | Baker Julian (10% Owner) | Buy | 398,062 | 16.29 | 6,483,633 |
| 2016-09-20 | Baker Julian (10% Owner) | Buy | 2,783,605 | 12.55 | 34,934,242 |
| 2016-03-16 | Baker Julian (10% Owner) | Buy | 361,755 | 7.92 | 2,865,461 |
| 2016-03-15 | Baker Julian (10% Owner) | Buy | 109,912 | 7.95 | 874,020 |
| 2016-01-26 | Baker Julian (10% Owner) | Buy | 77,639 | 10.90 | 846,265 |
| 2016-01-25 | Baker Julian (10% Owner) | Buy | 10,945 | 11.14 | 121,894 |
| 2016-01-22 | Baker Julian (10% Owner) | Buy | 52,202 | 10.69 | 558,091 |
| 2016-01-20 | Baker Julian (10% Owner) | Buy | 112,034 | 9.18 | 1,027,911 |
| 2016-01-19 | Baker Julian (10% Owner) | Buy | 78,045 | 9.15 | 713,955 |
| 2016-01-15 | Baker Julian (10% Owner) | Buy | 84,670 | 8.61 | 728,924 |
| 2016-01-14 | Baker Julian (10% Owner) | Buy | 117,953 | 8.05 | 949,875 |
| 2015-09-10 | Baker Julian (10% Owner) | Buy | 2,480,032 | 15.50 | 38,440,496 |
| 2015-08-24 | Mitchell David Chilton (VP Global Regulatory & Quality) | Buy | 3,575 | 17.81 | 63,670 |
| 2015-08-12 | Mackenzie Lloyd (VP Technical Operations) | Sale | 35,887 | 18.67 | 670,010 |
| 2015-08-12 | Mackenzie Lloyd (VP Technical Operations) | Option Ex | 35,887 | 5.76 | 206,709 |
| 2015-08-12 | Alam Kamran (CFO, Vice President Finance) | Sale | 29,079 | 18.67 | 542,904 |
| 2015-08-12 | Alam Kamran (CFO, Vice President Finance) | Option Ex | 29,079 | 5.76 | 167,495 |
| 2015-08-11 | Mitchell David Chilton (VP Global Regulatory & Quality) | Buy | 1,600 | 24.36 | 38,976 |
| 2015-08-11 | Johnson & Johnson Innovation - Jjdc, Inc. (10% Owner) | Sale | 1,283,366 | 20.74 | 26,617,010 |
| 2015-08-10 | Johnson & Johnson Innovation - Jjdc, Inc. (10% Owner) | Sale | 231,455 | 31.66 | 7,327,865 |
| 2015-08-10 | Pfizer Inc (10% Owner) | Sale | 259,927 | 30.43 | 7,910,098 |
| 2014-12-17 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 1,593 | 7.58 | 12,074 |
| 2014-12-16 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 6,507 | 7.63 | 49,648 |
| 2014-12-12 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 3,645 | 7.51 | 27,373 |
| 2014-12-11 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 1,355 | 7.50 | 10,162 |
| 2014-12-10 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 1,300 | 7.70 | 10,010 |
| 2014-12-09 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 5,000 | 7.73 | 38,650 |
| 2014-12-08 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 2,000 | 7.69 | 15,380 |
| 2014-12-05 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 4,200 | 7.78 | 32,676 |
| 2014-12-04 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 10,073 | 7.76 | 78,166 |
| 2014-12-03 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 1,627 | 7.75 | 12,609 |
| 2014-12-01 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 1,200 | 7.54 | 9,048 |
| 2014-11-26 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 500 | 7.60 | 3,800 |
| 2014-11-25 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 1,500 | 7.80 | 11,700 |
| 2014-11-24 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 4,000 | 8.02 | 32,080 |
| 2014-11-21 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 2,400 | 8.25 | 19,800 |
| 2014-11-20 | Johnson & Johnson Development Corp Et Al (10% Owner) | Sale | 3,100 | 8.21 | 25,451 |
| 2014-03-12 | Pfizer Inc (10% Owner) | Buy | 272,727 | 11.00 | 2,999,997 |
Insider trading activities including stock purchases, stock sales, and option exercises of NGNE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Neurogene Inc. (symbol NGNE, CIK number 1404644) see the Securities and Exchange Commission (SEC) website.